Aripiprazole is an atypical antipsychotic with partial D2 agonist activity, used for schizophrenia, bipolar disorder, and depression.
Also known as: aripiprazole, abilify
Antipsychotic + CYP3A4 inhibitor: ritonavir may increase aripiprazole levels.
Ritonavir inhibits CYP3A4, one of the metabolic pathways for aripiprazole. Levels may increase.
Signs of akathisia, sedation.
Reduce aripiprazole dose. Monitor adverse effects.
DailyMed/FDA; EMC-EMC PT
Antipsychotic + CYP2D6 inhibitor: fluoxetine may increase aripiprazole levels.
Fluoxetine inhibits CYP2D6, the main metabolic pathway for aripiprazole. Levels may increase 30-40%.
Signs of akathisia, agitation.
Severe akathisia.
Reduce aripiprazole dose by 50% if combined with potent CYP2D6 inhibitor.
DailyMed/FDA; EMC-EMC PT
No documented food or drink interactions.
No documented disease interactions.
No documented pregnancy or breastfeeding information.
Clinical and educational support tool. The information does not replace a medical prescription or the opinion of a qualified healthcare professional.
Partial D2 agonist and 5-HT1A agonist, 5-HT2A antagonist. Unique profile — dopaminergic stabiliser.
Partial D2 agonism: in hyperdopaminergic areas (antipsychotic effect) and hypodopaminergic areas (antidepressant effect). More benign profile than typical antipsychotics.
Good oral absorption. Bioavailability: 87%. Food does not affect.
Metabolised by CYP2D6 and CYP3A4. Dehydroaripiprazole (active metabolite, 30% of activity).
75 h (aripiprazole); 94 h (dehydroaripiprazole).
Medicines from the same therapeutic group (ATC classification) or the same pharmacological class.
